Effect of measles prevalence and vaccination coverage on other disease burden: evidence of measles immune amnesia in 46 African countries

References

• Minal P, Goodson J, Alexander J, Kretsinger J, Samir S, Steulet C, Gacic-Dobo M, Rota P, McFarland J, Menning L, et al. Progress toward regional measles elimination—worldwide, 2000–2019. Morbidity Mortality Weekly Report. 2020;69(45): 1700–05. doi:10.15585/mmwr.mm6945a6.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Measles. Regional Office for Africa; 2021 [accessed 2021 Aug 1]. https://www.afro.who.int/health-topics/measles.
   Google Scholar
• World Health Organization. Measles vaccines: WHO position paper. Weekly Epidemiological Record= Relevé épidémiologique hebdomadaire. 2009;84(35): 349–60.
   PubMedGoogle Scholar
• Goodson JL, Masresha BG, Wannemuehler K, Uzicanin A, Cochi S. Changing epidemiology of measles in Africa. J Infect Dis. 2011;204(suppl_1): S205–S214. doi:10.1093/infdis/jir129.
   PubMed Web of Science ®Google Scholar
• Anderson R, May R. Vaccination and herd immunity to infectious diseases. Nature. 1985;318(6044): 323–29. doi:10.1038/318323a0.
   PubMed Web of Science ®Google Scholar
• Mina M, Metcalf J, De Swart R, Osterhaus A, Grenfell B. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. Science. 2015;348(6235): 694–99. doi:10.1126/science.aaa3662.
   PubMed Web of Science ®Google Scholar
• Mina MJ. Measles, immune suppression and vaccination: direct and indirect nonspecific vaccine benefits. J Infect. 2017;74: S10–S17. doi:10.1016/S0163-4453(17)30185-8.
   PubMed Web of Science ®Google Scholar
• Chevalier-Cottin E-P, Ashbaugh H, Brooke N, Gavazzi G, Santillana M, Burlet N, Htar MTT. Communicating benefits from vaccines beyond preventing infectious diseases. Infectious Dis Thera. 2020:9:467-480.
   PubMed Web of Science ®Google Scholar
• Mina MJ, Kula T, Leng Y, Mamie L, De Vries RD, Knip M, Siljander H, Rewers M, Choy DF, Wilson MS, et al. Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. Science. 2019;366(6465): 599–606. doi:10.1126/science.aay6485.
   PubMed Web of Science ®Google Scholar
• Morales GB, Muñoz MA. Immune amnesia induced by measles and its effects on concurrent epidemics. J Royal Soc Interface. 2021;18(179): 20210153. doi:10.1098/rsif.2021.0153.
   PubMed Web of Science ®Google Scholar
• Behrens L, Cherry JD, Heininger U. The susceptibility to other infectious diseases following measles during a three year observation period in Switzerland. Pediatr Infect Dis J. 2020;39(6): 478–82. doi:10.1097/INF.0000000000002599.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Soares-Weiser K, Reingold A. Systematic review of the non-specific effects of BCG, DTP and measles containing vaccines. World Health Organization Report; 2014.
   Google Scholar
• Ashbaugh H, Cherry J, Hoff N, Doshi R, Alfonso V, Gadoth A, Mukadi P, Higgins S, Budd R, Randall C, et al. Association of previous measles infection with markers of acute infectious disease among 9-to 59-month-old children in the Democratic Republic of The Congo. J Pediatric Infect Dis Soc. 2019;8(6): 531–38. doi:10.1093/jpids/piy099.
   PubMed Web of Science ®Google Scholar
• Ashbaugh H, Cherry JD, Sue Gerber SG, Higgins AG, Alfonso VH, Mukadi P, Hoff N, Doshi R, Rimoin AW. Reported history of measles and long-term impact on antibody to tetanus in children 6–59 months of age receiving DTP in the Democratic Republic of Congo. Open Forum Infect Dis. 2017;4(suppl_1): S323–S323. US: Oxford University Press. doi:10.1093/ofid/ofx163.761.
   Google Scholar
• MacIntyre CR, Costantino V, Heslop DJ. The potential impact of a recent measles epidemic on COVID-19 in Samoa. BMC Infect Dis. 2020;20: 1–6.
   Web of Science ®Google Scholar
• Ozawa S, Mirelman A, Stack ML, Walker DG, Levine OS. Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: a systematic review. Vaccine. 2012;31(1): 96–108. doi:10.1016/j.vaccine.2012.10.103.
   PubMed Web of Science ®Google Scholar
• Kaucley L, Levy P. Cost-effectiveness analysis of routine immunization and supplementary immunization activity for measles in a health district of Benin. Cost Eff Res Allocation. 2015;13(1): 1–12. doi:10.1186/s12962-015-0039-7.
   PubMed Web of Science ®Google Scholar
• Khetsuriani N, Deshevoi S, Goel A, Spika J, Martin R, Emiroglu N. Supplementary immunization activities to achieve measles elimination: experience of the European Region. J Infect Dis. 2011;204(suppl_1): S343–S352. doi:10.1093/infdis/jir074.
   PubMed Web of Science ®Google Scholar
• Bishai D, Johns B, Nair D, Nabyonga-Orem J, Fiona-Makmot B, Simons E, Dabbagh A. The cost-effectiveness of supplementary immunization activities for measles: a stochastic model for Uganda. J Infect Dis. 2011;204(suppl_1): S107–S115. doi:10.1093/infdis/jir131.
   PubMed Web of Science ®Google Scholar
• Hayman DTS. Measles vaccination in an increasingly immunized and developed world. Hum Vaccin Immunother. 2019;15(1): 28–33. doi:10.1080/21645515.2018.1517074.
   PubMed Web of Science ®Google Scholar